Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
09
06
2020
accepted:
05
11
2020
revised:
29
12
2020
pubmed:
16
12
2020
medline:
29
1
2021
entrez:
15
12
2020
Statut:
epublish
Résumé
The rapid and aggressive spread of artemisinin-resistant Plasmodium falciparum carrying the C580Y mutation in the kelch13 gene is a growing threat to malaria elimination in Southeast Asia, but there is no evidence of their spread to other regions. We conducted cross-sectional surveys in 2016 and 2017 at two clinics in Wewak, Papua New Guinea (PNG) where we identified three infections caused by C580Y mutants among 239 genotyped clinical samples. One of these mutants exhibited the highest survival rate (6.8%) among all parasites surveyed in ring-stage survival assays (RSA) for artemisinin. Analyses of kelch13 flanking regions, and comparisons of deep sequencing data from 389 clinical samples from PNG, Indonesian Papua and Western Cambodia, suggested an independent origin of the Wewak C580Y mutation, showing that the mutants possess several distinctive genetic features. Identity by descent (IBD) showed that multiple portions of the mutants' genomes share a common origin with parasites found in Indonesian Papua, comprising several mutations within genes previously associated with drug resistance, such as mdr1, ferredoxin, atg18 and pnp. These findings suggest that a P. falciparum lineage circulating on the island of New Guinea has gradually acquired a complex ensemble of variants, including kelch13 C580Y, which have affected the parasites' drug sensitivity. This worrying development reinforces the need for increased surveillance of the evolving parasite populations on the island, to contain the spread of resistance.
Identifiants
pubmed: 33320907
doi: 10.1371/journal.ppat.1009133
pii: PPATHOGENS-D-20-01233
pmc: PMC7771869
doi:
Substances chimiques
Anti-Infective Agents
0
Artemisinins
0
artemisinin
9RMU91N5K2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1009133Subventions
Organisme : Medical Research Council
ID : G0600718
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206194
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 090770/Z/09/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204911/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M006212/1
Pays : United Kingdom
Organisme : World Health Organization
ID : 001
Pays : International
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet Infect Dis. 2016 Mar;16(3):357-65
pubmed: 26774243
Exp Parasitol. 2001 Jan;97(1):50-4
pubmed: 11207114
Malar J. 2018 Nov 26;17(1):434
pubmed: 30477515
PLoS One. 2015 Aug 20;10(8):e0136099
pubmed: 26292024
J Infect Dis. 2011 Dec 15;204(12):1980-8
pubmed: 22021623
Bioinformatics. 2019 Feb 1;35(3):526-528
pubmed: 30016406
Mol Biol Evol. 2017 Jan;34(1):131-144
pubmed: 28025270
PLoS One. 2018 May 29;13(5):e0197369
pubmed: 29813085
Science. 2015 Jan 23;347(6220):428-31
pubmed: 25502314
Nature. 2012 Jul 19;487(7407):375-9
pubmed: 22722859
Science. 2018 Jan 12;359(6372):191-199
pubmed: 29326268
Genetics. 2014 Jun;197(2):573-89
pubmed: 24700103
N Engl J Med. 2016 Jun 23;374(25):2453-64
pubmed: 27332904
Malar J. 2017 Jan 9;16(1):23
pubmed: 28068997
J Infect Dis. 2010 May 15;201(10):1551-60
pubmed: 20367478
J Infect Dis. 2012 Aug 1;206(3):324-32
pubmed: 22615315
Nat Genet. 2015 Mar;47(3):226-34
pubmed: 25599401
Lancet Infect Dis. 2019 Sep;19(9):943-951
pubmed: 31345709
Malar J. 2016 Dec 20;15(1):597
pubmed: 27998271
Lancet Infect Dis. 2017 Feb;17(2):174-183
pubmed: 27818097
Am J Trop Med Hyg. 2018 Mar;98(3):677-682
pubmed: 29345221
Lancet Infect Dis. 2017 Feb;17(2):164-173
pubmed: 27818095
Malar J. 2019 Nov 12;18(1):364
pubmed: 31718659
PLoS Negl Trop Dis. 2020 May 7;14(5):e0008295
pubmed: 32379762
Sci Rep. 2016 Oct 03;6:33891
pubmed: 27694982
Nature. 2014 Jan 2;505(7481):50-5
pubmed: 24352242
PLoS Genet. 2018 May 23;14(5):e1007279
pubmed: 29791438
Sci Transl Med. 2019 Jan 2;11(473):
pubmed: 30602534
Nature. 2002 Oct 24;419(6909):832-7
pubmed: 12397357
Bull World Health Organ. 2017 Oct 1;95(10):695-705B
pubmed: 29147042
Lancet Infect Dis. 2018 Mar;18(3):337-345
pubmed: 29398391
Emerg Infect Dis. 2018 Apr;24(4):718-726
pubmed: 29553316
Nature. 2000 Feb 24;403(6772):906-9
pubmed: 10706290
Mol Microbiol. 2005 Aug;57(4):913-26
pubmed: 16091034
Science. 2020 Jan 3;367(6473):51-59
pubmed: 31896710
Elife. 2016 Mar 04;5:
pubmed: 26943619
N Engl J Med. 2009 Jul 30;361(5):455-67
pubmed: 19641202
Malar J. 2017 Jan 13;16(1):27
pubmed: 28086775
Antimicrob Agents Chemother. 2016 May 23;60(6):3340-7
pubmed: 27001814
J Infect Dis. 2016 May 1;213(9):1472-5
pubmed: 26690347
N Engl J Med. 2014 Jul 31;371(5):411-23
pubmed: 25075834
Nat Methods. 2018 Jul;15(7):475-476
pubmed: 29967506
Malar J. 2012 Mar 28;11:92
pubmed: 22453078
Malar J. 2018 May 15;17(1):196
pubmed: 29764422
Malar J. 2018 Oct 5;17(1):350
pubmed: 30290825
Lancet Infect Dis. 2013 Dec;13(12):1043-9
pubmed: 24035558
Nature. 2002 Jul 18;418(6895):320-3
pubmed: 12124623